PMPRB

Proposed Practice Directions on Mode of Hearings, Document Exchange, Motions, Filing, AI Use, Virtual Proceedings

The Patented Medicine Prices Review Board (PMPRB) is consulting on seven proposed practice directions to modernize its hearing procedures. The directions address mode of hearings (defaulting to paper hearings for evidentiary portions), document exchange facilitation, motion standardization, electronic filing and page limits, expedited failure-to-file proceedings, use of artificial intelligence in proceedings, and virtual proceedings. Stakeholders may submit comments on these proposed directions.

PMPRB News Archive Results Page

The Patented Medicine Prices Review Board (PMPRB) published a news archive search results page displaying 79 results. The page serves as a navigational interface to the PMPRB's published news content on Canada.ca.

PMPRB Releases New Guidelines for Drug Price Monitoring Effective January 1

The Patented Medicine Prices Review Board (PMPRB) has released new guidelines governing how staff monitor and review patented drug prices in Canada. The guidelines establish updated procedures for price excessive price hearings and related administrative processes. The new guidelines take effect January 1, 2025.

Public Drug Plan Spending Rose $3.4B Over 5 Years Driven by High-Cost Drugs

The PMPRB released its CompassRx 10th edition report showing Canadian public drug plan prescription spending grew 7.4% in 2022/23 to $14.1 billion from $13.2 billion in 2021/22. Over five years (2017/18 to 2022/23), total spending rose by $3.4 billion with a compound annual growth rate of 5.9%. Drugs costing over $10,000 annually were used by less than 3% of beneficiaries yet accounted for over one-third of total drug costs.

2024 PMPRB Annual Report Shows $22.1B Patented Medicine Sales

The Patented Medicine Prices Review Board (PMPRB) has tabled its 2024 Annual Report in Parliament. The report documents $22.1 billion in sales of patented medicines in Canada for the reporting period. PMPRB continues its role as Canada's federal board responsible for reviewing patented medicine prices to ensure they are not excessive.